Financial Performance - Net profit attributable to shareholders rose by 15.30% to ¥15,333,397.76 for the first nine months of 2023[11] - Operating revenue for the first nine months increased by 8.39% to ¥102,592,617.84 compared to the same period last year[11] - Basic earnings per share for the first nine months increased by 13.16% to ¥0.43[11] - The company reported a net profit of ¥4,280,076.53 for Q3 2023, a decrease of 40.84% compared to Q3 2022[11] - Total operating revenue for the first nine months of 2023 reached ¥102,592,617.84, an increase of 8.9% compared to ¥94,647,558.81 in the same period of 2022[41] - Net profit for the first nine months of 2023 was ¥15,333,397.76, representing a 15.4% increase from ¥13,298,296.82 in 2022[43] - Basic earnings per share for the first nine months of 2023 were ¥0.43, compared to ¥0.38 in the same period of 2022, reflecting a growth of 13.2%[44] - Operating profit for the first nine months of 2023 was CNY 19,192,333.75, up from CNY 17,120,248.17 in 2022, reflecting a growth of 12.1%[46] - Net profit for the first nine months of 2023 reached CNY 16,796,588.11, an increase of 15.5% compared to CNY 14,541,631.37 in the same period of 2022[46] Assets and Liabilities - Total assets increased by 38.45% to ¥269,617,025.45 compared to the end of last year[11] - The company's debt-to-asset ratio decreased to 21.37% from 35.87% at the end of last year[11] - The total liabilities decreased to CNY 57,607,462.25 from CNY 69,848,670.56, showing a reduction of about 17.5%[35] - The company's equity attributable to shareholders rose to CNY 212,009,563.20, up from CNY 124,888,922.30, marking an increase of approximately 69.7%[35] - The total assets of the company rose to ¥269,843,066.02 in 2023, compared to ¥193,065,767.14 in 2022, indicating an increase of approximately 39.7%[39] - Total liabilities decreased to ¥56,627,481.13 in 2023 from ¥68,434,013.50 in 2022, indicating a reduction of approximately 17.3%[39] - Total equity increased significantly to ¥213,215,584.89 in 2023 from ¥124,631,753.64 in 2022, marking an increase of about 70.9%[39] Cash Flow - Cash flow from operating activities improved by 40.11%, reaching -¥7,108,299.20[11] - Cash flow from operating activities for the first nine months of 2023 was negative CNY 7,108,299.20, an improvement from negative CNY 11,868,441.45 in the same period of 2022[47] - Total cash inflow from operating activities was CNY 85,346,165.75, compared to CNY 67,331,781.29 in 2022, indicating a growth of 26.7%[47] - Cash flow from investing activities showed a net outflow of CNY 56,780,059.91, compared to a much smaller outflow of CNY 43,443.89 in the previous year[48] - Cash flow from financing activities generated a net inflow of CNY 72,226,157.39, a significant recovery from a net outflow of CNY 12,624,528.00 in 2022[48] - The ending cash and cash equivalents balance for the first nine months of 2023 was CNY 87,958,142.35, up from CNY 39,361,519.11 at the end of 2022[48] Shareholder Information - The total number of unrestricted shares increased from 3,792,000 to 10,985,100, representing a growth of 189.5%[20] - The proportion of unrestricted shares held by major shareholders rose from 10.83% to 25.35%[20] - The total share capital increased from 35,000,000 to 43,333,100 shares, marking an increase of 24%[20] - The largest shareholder, Lv Mingjie, holds 60.33% of the total shares, remaining unchanged during the reporting period[21] Other Financial Metrics - Significant increase in accounts receivable by 343.47% to ¥26,625,711.47 due to changes in sales rebate assessments[12] - The company issued shares to unspecified qualified investors, resulting in a capital reserve increase of 124.09% to ¥114,590,131.66[12] - Non-recurring gains totaled CNY 1,890,849.08, with a net amount of CNY 1,606,993.83 after tax effects[15] - Deferred tax assets increased from CNY 1,728,175.45 to CNY 1,835,126.47 year-over-year, reflecting a growth of approximately 6.5%[18] - Research and development expenses for the first nine months of 2023 were ¥5,258,696.12, slightly down from ¥6,188,392.93 in 2022, a decrease of 15%[42] - The company reported a financial income of ¥486,335.51 in 2023, a substantial increase from ¥126,224.55 in 2022, representing a growth of 285.5%[42] - Deferred income increased to ¥1,492,750.00 in 2023 from ¥657,000.00 in 2022, reflecting a growth of 127.6%[39] Compliance and Legal Matters - There were no significant legal disputes or external guarantees reported during the period[26] - The company has not engaged in any share buyback activities during the reporting period[26] - The company has maintained compliance with all major events and disclosures as required[26] - The company reported a daily related party transaction amount of CNY 271,946.25 against an estimated amount of CNY 400,000.00[27] - The company reported no overdue commitments during the reporting period, with all commitments being fulfilled as per the disclosed terms[29]
博迅生物(836504) - 2023 Q3 - 季度财报